Approaches to preventing, treating and living with macular degeneration discussed at Academy meeting

November 18, 2003

ANAHEIM, Calif. - Leading researchers discussed the latest breakthroughs in the prevention and treatment of age-related macular degeneration (AMD), and methods of visual rehabilitation, at the Annual Meeting of the American Academy of Ophthalmology, the Eye M.D. Association.

Mortality and Nutritional Risk Factors Emily Y. Chew, MD, medical officer at the Division of Biometry and Epidemiology, National Eye Institute presented updated information from the Age Related Eye Disease Study (AREDS). The study assessed the effect of vitamin and mineral supplementation on the onset and progression of AMD. The latest AREDS findings show there is a high correlation of mortality and advanced AMD. Study participants who took only zinc had the lowest mortality rate. "AMD may be more of a systemic disease than just an ocular disease," she said.

Surgery and Steroid Treatment for AMD

William F. Mieler, MD, professor of ophthalmology at Baylor College of Medicine, reviewed the history and current status of surgical approaches to treating AMD. He also reported on the promising results of Phase II/III clinical trials of anecortave acetate, a steroid analog injected into the eye that significantly reduces loss of vision. "The 24-month results show this is a safe and effective treatment for AMD," said Dr. Mieler. "Future studies will assess a depot delivery system that does not require injections into the eye."

Macugen and Other Anti-VEGF Drugs

Lawrence Singerman, MD, clinical professor of ophthalmology at Case Western Reserve University School of Medicine, discussed the recently approved drug Macugen (pegaptanib sodium). It has been found to significantly reduce the loss of vision in patients with all types of AMD, and to regain vision in 33 percent of patients. This drug was also successfully used to treat larger AMD lesions. "Eventually, we won't have to choose just one drug approach, just like we see in cancer therapy," said Dr. Singerman.

Visual Rehabilitation

Lylas G. Mogk, MD, director of the Visual Rehabilitation and Research Center of the Henry Ford Health System and chair of the Academy's Vision Rehabilitation Committee, spoke on the impact of vision loss and visual rehabilitation. "Every year 200,000 people lose central vision for AMD, most of which is not treatable with current medical approaches," she said. "Vision impairment causes more loss of function than any other physical impairment. There are also higher rates of depression with vision loss compared with heart disease, lung disease and cancer. Fortunately there is good news. Visual rehabilitation can help people do home-based activities and remain active in the community."
-end-
The American Academy of Ophthalmology is the world's largest association of eye physicians and surgeons--Eye M.D.s--with more than 27,000 members worldwide. For more information about eye health care, visit the Academy's partner Web site, the Medem Network, at http://www.medem.com/eyemd. To find an Eye M.D. in your area, visit the Academy's Web site at http://www.aao.org.

American Academy of Ophthalmology

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.